Polymeric-hydroxyapatite bone composite

• US 5,766,618 A
• Filed: 03/05/1997
• Issued: 06/16/1998
• Est. Priority Date: 04/01/1994
• Status: Expired due to Fees

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Devin, Jessica, Attawia, Muhammed, Laurencin, Cato T.
• Primary Examiner(s): AZPURU, CARLOS A
• Application Number:
  US08/811,582
• Time in Patent Office: 468 Days
• Field of Search: 424/426, 424/501
• US Class Current: 424/426
• CPC Class Codes: A61F 2/28 Bones joints A61F2/30
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 27/46 with phosphorus-containing inorganic fillers
• CPC Class Codes: A61L 27/58 Materials at least partially resorbable by the body
• CPC Class Codes: C08L 67/00 Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain of polyester-amides C08L77/12; of polyester-imides C08L79/08; Compositions of derivatives of such polymers
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence
• CPC Class Codes: C08L 73/02 Polyanhydrides
• CPC Class Codes: C08L 85/02 containing phosphorus

Abstract

A method for the fabrication of three-dimensional macroporous polymer matrices for use as bone graft or implant material was developed. The composites are formed from a mixture of biodegradable, biocompatible polymer and hydroxyapatite (HA), a particulate calcium phosphate ceramic. The method leaves irregular pores in the composite between 100 and 250 microns in size. In a preferred embodiment, implants are composed of a 50:50 poly(lactide-co-glycolide) (PLGA) polymer and reinforced by hydroxyapatite. Mechanical and histological analysis showed the matrix fabricated by this method to be structurally and mechanically similar to cancellous bone. Prior to degradation, pure polymer specimens exhibited an elastic modulus of 293 MPa and specimens which were 50% HA by weight exhibited a modulus of 1459 MPa. After six weeks of degradation under physiological conditions, the reinforcing effect of ceramic loading had diminished. Modulus of polymer matrices at all HA load levels had decreased sharply to approximately 10 MPa. Mean macro- and micropore diameters of the polymer specimens were 100 μm and 20 μm respectively and remained constant throughout degradation.

Claims

1. A porous composite comprising hydroxyapatite particles having a diameter in the range of between approximately 10 microns and 100 microns mixed with a biodegradable, biocompatible polymer wherein the pores have a diameter in the range of between approximately 100 and 250 microns.

2. The composite of claim 1 wherein the biodegradable, biocompatible polymer is selected from the group consisting of polyanhydrides, polyhydroxy acids, polyorthoesters, polyphosphazenes, blends thereof, and copolymers thereof.

3. The composite of claim 1 further comprising osteoblasts.

4. The composite of claim 1 wherein the hydroxyapatite is selected from the group consisting of natural and synthetic hydroxyapatite, bone, cementum, dentin, enamel, tricalcium phosphate, calcium phosphate (CaPO₄), and combinations thereof.

5. The composite of claim 1 further comprising a biologically active material selected from the group consisting of antibiotics, chemotherapeutics, bone cell inducers and bone cell stimulators.

11. The composite of claim 1 wherein the hydroxyapatite comprises organic material and ions.

6. A process for treating a bone defect comprising implanting at the site of the defect a porous composite comprising hydroxyapatite particles having a diameter in the range of between approximately 10 microns and 100 microns mixed with a biodegradable, biocompatible polymer wherein the pores have a diameter in the range of between approximately 100 and 250 microns.

7. The process of claim 6 wherein the polymer is selected from the group consisting of polyanhydrides, polyhydroxy acids, polyorthoesters, polyphosphazenes, and blends and copolymers thereof.

8. The process of claim 6 further comprising seeding the composite with osteoblasts prior to implantation.

9. The process of claim 6 wherein the hydroxyapatite is selected from the group consisting of natural and synthetic hydroxyapatite, bone, cementum, dentin, enamel, tricalcium phosphate, calcium phosphate (CaPO₄), and combinations thereof.

10. The process of claim 6 further comprising administering at the site of implantation a biologically active material selected from the group consisting of antibiotics, chemotherapeutics, bone cell inducers and bone cell stimulators.

12. The process of claim 6 wherein the hydroxyapatite comprises organic material and ions.